TP53 and cancer: These enriched pathways reflect key physiopathological mechanisms of cancer therapy–related cardiotoxicity, including anthracycline-induced DNA damage and p53-mediated apoptosis, oxidative and mitochondrial stress, disruption of cytoskeletal and focal adhesion integrity, and maladaptive MAPK-driven hypertrophic and fibrotic remodeling.